Egalet Corp. said its abuse-deterrent opioid, Egalet-002, met its main goal in a phase 3 study.
Under the trial, the extended-release oxycodone showed a statistically significant difference in average pain intensity from baseline to week 16 compared to placebo in opioid-experienced and opioid-naïve patients with moderate-to-severe chronic low back pain.
The study is the second of two phase 3 studies evaluating Egalet-002. Under the previously announced phase 3 safety study, the treatment was generally well tolerated and no new safety concerns were identified.
